Literature DB >> 378859

Immunotherapy of guinea pigs with dermal and visceral tumor implants: comparison of living and nonliving BCG.

E Yarkoni, L Peters, H J Rapp, M G Hanna, J T Hunter.   

Abstract

Emulsified cell walls of Mycobacterium bovis (BCG) were immunotherapeutically at least as active as living BCG in prolonging survival of guinea pigs with established dermal tumors and microscopic lymph node and visceral metastases.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 378859      PMCID： PMC414338          DOI： 10.1128/iai.24.2.565-566.1979

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  9 in total

1.  Treatment of malignant melanoma by intratumoral injection of BCG.

Authors:  C M Pinsky; Y Hirshaut; H F Oettgen
Journal:  Natl Cancer Inst Monogr       Date:  1973-12

2.  Immunoprophylaxis of malignant melanoma with systemic BCG: study of strain, dose, and schedule.

Authors:  J U Gutterman; G Mavligit; C McBride; E Frei; E M Hersh
Journal:  Natl Cancer Inst Monogr       Date:  1973-12

3.  Immunotherapy of cancer: regression of established intradermal tumors after intralesional injection of mycobacterial cell walls attached to oil droplets.

Authors:  B Zbar; E Ribi; T Meyer; I Azuma; H J Rapp
Journal:  J Natl Cancer Inst       Date:  1974-05       Impact factor: 13.506

Review 4.  A guinea pig model for tumor immunology. A summary.

Authors:  H J Rapp
Journal:  Isr J Med Sci       Date:  1973-03

5.  Active immunotherapy with B.C.G. for recurrent malignant melanoma.

Authors:  J U Gutterman; G Mavligit; C McBride; E Frei; E J Freireich; E M Hersh
Journal:  Lancet       Date:  1973-06-02       Impact factor: 79.321

6.  Immunotherapy in patients with melanoma.

Authors:  H F Seiger; W W Shingleton; R S Metzgar; C E Buckley
Journal:  Ann Surg       Date:  1973-09       Impact factor: 12.969

7.  Immunological factors in human sarcomas and melanomas: a rational basis for immunotherapy.

Authors:  D L Morton; F R Eilber; W L Joseph; W C Wood; E Trahan; A S Ketcham
Journal:  Ann Surg       Date:  1970-10       Impact factor: 12.969

8.  Regional immunotherapy of lung cancer with intrapleural B.C.G.

Authors:  M F McKneally; C Maver; H W Kausel
Journal:  Lancet       Date:  1976-02-21       Impact factor: 79.321

9.  Clinical and immunologic studies of disseminated BCG infection.

Authors:  S A Rosenberg; C Seipp; H F Sears
Journal:  Cancer       Date:  1978-05       Impact factor: 6.860
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.